{
    "nctId": "NCT00323479",
    "briefTitle": "Arthralgia During Anastrozole Therapy for Breast Cancer",
    "officialTitle": "A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX\u00ae (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Early Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 114,
    "primaryOutcomeMeasure": "Number of Participants With New Events of Arthralgia",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole\n* WHO performance status 0, 1 or 2\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Recurrence of breast cancer, inflammatory rheumatism\n* treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin\n* Diabetes treated by insulin\n* Severe renal or hepatic disease\n* Known hypersensitivity to anastrozole",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}